An Update on the Current Epidemiological Situation Regarding Glycopeptide-Resistant Staphylococcus aureus (Vancomycin and Teicoplanin) in France

Published on 6 June 2000 Updated on 9 September 2019

For more than thirty years, vancomycin has been considered the antibiotic of choice for treating methicillin-resistant Staphylococcus aureus (MRSA) infections. However, MRSA strains with reduced or intermediate susceptibility to glycopeptides (vancomycin or teicoplanin) have been isolated in infections that failed treatment with these antibiotics, and others following cross-transmission. Based on the data presented, it appears that the change in S. aureus susceptibility to glycopeptides has been an evolving phenomenon over the past few years rather than an emerging one.

Author(s): Allouch PY, Astagneau P, Aubry Damon H, Bismuth R, Brun Buisson C, Buu Hoi A, Carlet J, Chesneau O, Chaperon J, Courvalin P, Desenclos JC, Drucker J, Drugeon H, El Solh N, Etienne J, Fabry J, Gutmann L, Jarlier V, Joly C, Kac G, Leclercq R, Legrand P, Mainardi JL, Meunier O, Parneix P, Pierre V, Podglajen I, Ploy MC, Rauss A, Reverdy ME, Savey A, Soussy CJ, Struelens MJ, Tran B

Publishing year: 2000

Pages: 97-9

Weekly Epidemiological Bulletin, 2000, n° 23, p. 97-9

Download pdf 1.38 MB